JP2004530655A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004530655A5 JP2004530655A5 JP2002567237A JP2002567237A JP2004530655A5 JP 2004530655 A5 JP2004530655 A5 JP 2004530655A5 JP 2002567237 A JP2002567237 A JP 2002567237A JP 2002567237 A JP2002567237 A JP 2002567237A JP 2004530655 A5 JP2004530655 A5 JP 2004530655A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- unsubstituted
- substituted
- alkoxy
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- 230000005865 ionizing radiation Effects 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 30
- 125000003107 substituted aryl group Chemical group 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 14
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000004404 heteroalkyl group Chemical group 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 7
- 125000004442 acylamino group Chemical group 0.000 claims 7
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- -1 phosphonato, amino Chemical group 0.000 claims 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 4
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000005466 alkylenyl group Chemical group 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims 3
- 229910052717 sulfur Chemical group 0.000 claims 3
- 239000011593 sulfur Chemical group 0.000 claims 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 2
- 239000000010 aprotic solvent Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- PJVVYXNQBRSHSZ-MDZDMXLPSA-N (e)-2-(4-chlorophenyl)-n-(4-fluorophenyl)ethenesulfonamide Chemical compound C1=CC(F)=CC=C1NS(=O)(=O)\C=C\C1=CC=C(Cl)C=C1 PJVVYXNQBRSHSZ-MDZDMXLPSA-N 0.000 claims 1
- DINXQBZMENCOKI-OUKQBFOZSA-N (e)-2-(4-methoxyphenyl)-n-methyl-n-phenylethenesulfonamide Chemical compound C1=CC(OC)=CC=C1\C=C\S(=O)(=O)N(C)C1=CC=CC=C1 DINXQBZMENCOKI-OUKQBFOZSA-N 0.000 claims 1
- HWNLDTIDRYBPGB-MDZDMXLPSA-N (e)-n-(2-chlorophenyl)-2-(4-chlorophenyl)ethenesulfonamide Chemical compound C1=CC(Cl)=CC=C1\C=C\S(=O)(=O)NC1=CC=CC=C1Cl HWNLDTIDRYBPGB-MDZDMXLPSA-N 0.000 claims 1
- HVYLDFAKCXWXQM-CMDGGOBGSA-N (e)-n-(3-chlorophenyl)-2-(4-chlorophenyl)ethenesulfonamide Chemical compound C1=CC(Cl)=CC=C1\C=C\S(=O)(=O)NC1=CC=CC(Cl)=C1 HVYLDFAKCXWXQM-CMDGGOBGSA-N 0.000 claims 1
- NBMJWPSGKBOEGM-ZHACJKMWSA-N (e)-n-(4-chlorophenyl)-2-phenylethenesulfonamide Chemical compound C1=CC(Cl)=CC=C1NS(=O)(=O)\C=C\C1=CC=CC=C1 NBMJWPSGKBOEGM-ZHACJKMWSA-N 0.000 claims 1
- NAVWKCWTWVEFGF-ZHACJKMWSA-N (e)-n-(4-fluorophenyl)-2-(4-methoxyphenyl)ethenesulfonamide Chemical compound C1=CC(OC)=CC=C1\C=C\S(=O)(=O)NC1=CC=C(F)C=C1 NAVWKCWTWVEFGF-ZHACJKMWSA-N 0.000 claims 1
- XMABHOFNENDQOQ-ZHACJKMWSA-N (e)-n-(4-fluorophenyl)-2-phenylethenesulfonamide Chemical compound C1=CC(F)=CC=C1NS(=O)(=O)\C=C\C1=CC=CC=C1 XMABHOFNENDQOQ-ZHACJKMWSA-N 0.000 claims 1
- CNXODVDGIBSDFK-MDZDMXLPSA-N (e)-n-(4-methoxyphenyl)-2-(2,4,6-trimethoxyphenyl)ethenesulfonamide Chemical compound C1=CC(OC)=CC=C1NS(=O)(=O)\C=C\C1=C(OC)C=C(OC)C=C1OC CNXODVDGIBSDFK-MDZDMXLPSA-N 0.000 claims 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 claims 1
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 claims 1
- WYFVQNOPCPSWRR-ZHACJKMWSA-N 4-[[(e)-2-(4-methoxyphenyl)ethenyl]sulfonylamino]benzenesulfonamide Chemical compound C1=CC(OC)=CC=C1\C=C\S(=O)(=O)NC1=CC=C(S(N)(=O)=O)C=C1 WYFVQNOPCPSWRR-ZHACJKMWSA-N 0.000 claims 1
- KTQFCPAZJBKJQK-ZHACJKMWSA-N 4-[[(e)-2-phenylethenyl]sulfonylamino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NS(=O)(=O)\C=C\C1=CC=CC=C1 KTQFCPAZJBKJQK-ZHACJKMWSA-N 0.000 claims 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 125000005805 dimethoxy phenyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000006501 nitrophenyl group Chemical group 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 125000001725 pyrenyl group Chemical group 0.000 claims 1
- 230000005855 radiation Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27198501P | 2001-02-28 | 2001-02-28 | |
| PCT/US2002/005979 WO2002067865A2 (en) | 2001-02-28 | 2002-02-28 | N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004530655A JP2004530655A (ja) | 2004-10-07 |
| JP2004530655A5 true JP2004530655A5 (enExample) | 2006-01-05 |
| JP4171656B2 JP4171656B2 (ja) | 2008-10-22 |
Family
ID=23037924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002567237A Expired - Fee Related JP4171656B2 (ja) | 2001-02-28 | 2002-02-28 | Ｎ−（アリール）−２−アリールエテンスルホンアミド及びその製薬用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6646009B2 (enExample) |
| EP (1) | EP1379508B9 (enExample) |
| JP (1) | JP4171656B2 (enExample) |
| KR (1) | KR100850330B1 (enExample) |
| AT (1) | ATE479657T1 (enExample) |
| AU (1) | AU2002306604B2 (enExample) |
| CA (1) | CA2439255C (enExample) |
| DE (1) | DE60237512D1 (enExample) |
| DK (1) | DK1379508T3 (enExample) |
| IL (2) | IL157540A0 (enExample) |
| WO (1) | WO2002067865A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6667346B2 (en) * | 2001-02-28 | 2003-12-23 | Temple University - Of The Commonwealth System Of Higher Education | Method for protecting cells and tissues from ionizing radiation toxicity with α, β unsaturated aryl sulfones |
| NZ535232A (en) * | 2002-02-28 | 2007-05-31 | Univ Temple | Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders |
| IL163608A0 (en) * | 2002-02-28 | 2005-12-18 | Univ Temple | Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders |
| AU2004289281C1 (en) * | 2003-11-14 | 2011-12-08 | Onconova Therapeutics, Inc. | Alpha, beta-Unsaturated sulfoxides for treating proliferative disorders |
| AU2005222947B2 (en) * | 2004-03-16 | 2010-12-23 | Onconova Therapeutics Inc. | Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders |
| WO2005090297A1 (en) * | 2004-03-19 | 2005-09-29 | Biotie Therapies Corporation | Sulphonamide derivatives |
| NZ574028A (en) | 2006-07-05 | 2010-10-29 | Fibrotech Therapeutics Pty Ltd | Tranilast analogues (substituted cinnamoyl anthranilate compounds) for treatment of conditions associated with firbrosis |
| US8664272B2 (en) | 2006-08-30 | 2014-03-04 | Temple University—Of the Commonwealth System of Higher Education | Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia |
| SG10201506526QA (en) * | 2007-12-21 | 2015-09-29 | Fibrotech Therapeutics Pty Ltd | Halogenated analogues of anti-fibrotic agents |
| WO2010144959A1 (en) * | 2009-06-18 | 2010-12-23 | Fibrotech Therapeutics Pty Ltd | Analogues of anti-fibrotic agents |
| EP2947073B1 (en) | 2009-10-22 | 2019-04-03 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
| WO2013039985A2 (en) * | 2011-09-12 | 2013-03-21 | The Johns Hopkins University | Serine protease inhibitors |
| US9730913B2 (en) | 2011-10-13 | 2017-08-15 | The Johns Hopkins University | High affinity beta lactamase inhibitors |
| CA2885217C (en) | 2012-09-20 | 2019-10-08 | Temple University - Of The Commonwealth System Of Higher Education | Substituted alkyl diaryl derivatives, methods of preparation and uses |
| US10383831B2 (en) | 2015-08-03 | 2019-08-20 | Temple University—Of the Commonwealth System of Higher Education | 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use |
| EP3577103A1 (en) | 2017-02-03 | 2019-12-11 | Certa Therapeutics Pty Ltd. | Anti-fibrotic compounds |
| JP2022517797A (ja) * | 2019-01-17 | 2022-03-10 | アイエフエム デュー インコーポレイテッド | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
| AU2022326463A1 (en) | 2021-08-10 | 2024-02-22 | Novartis Pharma Ag | Compounds and compositions for treating conditions associated with sting activity |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2531367A (en) * | 1947-07-15 | 1950-11-21 | Sharp & Dohme Inc | N-(substituted sulfonyl)-aminobenzoic acids |
| DE2118493C3 (de) | 1971-04-16 | 1980-04-30 | Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung von Aminostilbenen |
| US4035421A (en) | 1976-03-19 | 1977-07-12 | Morton-Norwich Products, Inc. | N-(3,4,-dichlorophenyl)-2-phenylethenesulfonamide |
| DE2809377A1 (de) * | 1978-03-04 | 1979-09-13 | Boehringer Mannheim Gmbh | Phenoxyalkylcarbonsaeure-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
| ZA915371B (en) | 1990-07-17 | 1993-03-31 | Lilly Co Eli | Antitumor compositions and methods of treatment |
| JPH04202173A (ja) * | 1990-11-30 | 1992-07-22 | Zeria Pharmaceut Co Ltd | スルホンアミド誘導体及びそれを含有する５―リポキシゲナーゼ阻害剤 |
| WO1995024190A2 (en) * | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| US5780483A (en) * | 1995-02-17 | 1998-07-14 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| JPH11503110A (ja) | 1995-02-17 | 1999-03-23 | スミスクライン・ビーチャム・コーポレイション | Ｉｌ−８受容体拮抗剤 |
| NZ331941A (en) * | 1996-02-22 | 2000-04-28 | Tularik Inc | Pentafluorobenzenesulfonamides and analogs and use in regulation of LDL receptor synthesis |
| US6191170B1 (en) * | 1998-01-13 | 2001-02-20 | Tularik Inc. | Benzenesulfonamides and benzamides as therapeutic agents |
| DK1115701T3 (da) | 1998-09-23 | 2003-06-23 | Tularik Inc | Arylsulfonanilidurinstoffer |
| US6586617B1 (en) * | 1999-04-28 | 2003-07-01 | Sumitomo Chemical Takeda Agro Company, Limited | Sulfonamide derivatives |
-
2002
- 2002-02-28 DK DK02802229.1T patent/DK1379508T3/da active
- 2002-02-28 EP EP02802229A patent/EP1379508B9/en not_active Expired - Lifetime
- 2002-02-28 WO PCT/US2002/005979 patent/WO2002067865A2/en not_active Ceased
- 2002-02-28 AT AT02802229T patent/ATE479657T1/de not_active IP Right Cessation
- 2002-02-28 JP JP2002567237A patent/JP4171656B2/ja not_active Expired - Fee Related
- 2002-02-28 DE DE60237512T patent/DE60237512D1/de not_active Expired - Lifetime
- 2002-02-28 KR KR1020037011303A patent/KR100850330B1/ko not_active Expired - Fee Related
- 2002-02-28 US US10/085,826 patent/US6646009B2/en not_active Expired - Lifetime
- 2002-02-28 AU AU2002306604A patent/AU2002306604B2/en not_active Ceased
- 2002-02-28 IL IL15754002A patent/IL157540A0/xx unknown
- 2002-02-28 CA CA2439255A patent/CA2439255C/en not_active Expired - Fee Related
-
2003
- 2003-08-21 IL IL157540A patent/IL157540A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004525908A5 (enExample) | ||
| HUP0102793A2 (hu) | Agydaganat kezelésére szolgáló kinazolinok és ezeket tartalmazó gyógyszerkészítmények | |
| JP2019014758A5 (enExample) | ||
| IS2114B (is) | Kínasólínafleiður til að meðhöndla æxli | |
| JP2007511504A5 (enExample) | ||
| PT1613315E (pt) | Derivados da quinolina-2-ona para o tratamento de doenças das vias aéreas respiratórias | |
| JP2009513662A5 (enExample) | ||
| JP2007529421A5 (enExample) | ||
| NZ515282A (en) | Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions | |
| RU99101081A (ru) | Режим введения ингибиторов н+, к+-атфазы | |
| DE60229046D1 (de) | Chinazolin derivate | |
| CA2439255A1 (en) | N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof | |
| JP2006501201A5 (enExample) | ||
| DE602004015277D1 (de) | Substituierte-1-phthalazinamine als vr-1-antagonisten | |
| NO20055655D0 (no) | Anvendelse av azetidinkarboksamidderivater i terapi | |
| NO20050569L (no) | Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette | |
| EP1583564A4 (en) | IMPROVED LINKERS FOR RADIO-PHARMACEUTICAL COMPOUNDS | |
| EE04777B1 (et) | Kasvajavastased ühendid, neid sisaldavad farmatseutilised kompositsioonid ning nende kasutamine | |
| CA2451241A1 (en) | Unsymmetrical cyclic diamine compound | |
| NO20050428L (no) | Arylkarbonylpiperaziner og heteroarylkarbonylpiperaziner og anvendelse derav for behandling av godartede og ondartede tumorsykdommer | |
| MXPA05005790A (es) | Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central. | |
| UA83832C2 (ru) | Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и их применение | |
| RU2003130644A (ru) | Производные ркарболина и их фармацевтическое применение против дипрессии и страха | |
| CA2461963A1 (en) | Cyclic amine compounds | |
| SE0104326D0 (sv) | Therapeutic heterocycles |